What's happening
This bill allows pharmacists to substitute lower-cost alternate epinephrine auto-injectors for brand name prescriptions under certain conditions.
Why it matters
Expands consumer choice and access. This bill enables pharmacists to offer patients lower-cost epinephrine auto-injectors (like generic or alternative brands), making these life-saving devices more affordable and accessible, especially for those facing high out-of-pocket costs or insurance limitations.
Patient protection and informed consent. The bill requires pharmacists to obtain explicit consent from the patient before substituting the prescribed auto-injector and to provide counseling on how to use the new device, reducing confusion and ensuring patients are comfortable with the substituted product.
Maintains prescriber authority. The legislation preserves the right of prescribers to require the exact brand if they specify “dispense as written,” allowing medical professionals to retain control when they deem it clinically necessary for their patient.
Addresses gaps in current substitution law. By allowing substitution even if the alternative device is not on the state’s official list of interchangeable drugs, the bill responds to the unique nature of epinephrine auto-injectors, for which device mechanics and training are critical, but cost and availability are frequent barriers.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Allow Generic EpiPen Substitutes
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to higher education
- Delivered to assembly
- Passed senateVote 63–0
- Advanced to third reading
- 2nd report cal.
- 1st report cal.511
- Referred to higher education
- Returned to senate
- Died in assembly
- Referred to higher education
- Delivered to assembly
- Passed senateVote 63–0
Show 4 earlier actions
- Advanced to third reading
- 2nd report cal.
- 1st report cal.1137
- Referred to higher education
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Allow Epinephrine Auto-Injector Substitutes
In Assembly Committee · Higher Education · Sponsor Thomas Abinanti
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6393
2021-2022 Regular Sessions
IN SENATE
April 26, 2021
Introduced by Sen. REICHLIN-MELNICK -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education
AN ACT to amend the education law, in relation to the substitution of brand name epinephrine auto-injectors with alternate epinephrine autoinjectors for dispensation by pharmacists
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 6816-a of the education law is amended by adding a new subdivision 6 to read as follows:
6. (a) Notwithstanding subdivision two of this section or any other section of law to the contrary, when a patient is prescribed a brand name epinephrine auto-injector, a pharmacist may substitute an alternate epinephrine auto-injector containing the same active ingredients, dosage form and strength as the brand name product prescribed, ordered or demanded, regardless of whether the alternate epinephrine auto-injector is included in the latest list of interchangeable drug products for the prescribed epinephrine auto-injector device, provided that:
(i) the prescriber does not indicate that the prescription therefor shall be dispensed as written pursuant to paragraph (a) of subdivision six of section sixty-eight hundred ten of this article;
(ii) the alternate epinephrine auto-injector available would reflect a lower unit cost to the purchaser;
(iii) the pharmacist has advised the purchaser of the availability of an alternate epinephrine auto-injector and obtained consent to dispense the alternate epinephrine auto-injector; and
(iv) the pharmacist has counseled the patient or person authorized to act on the patient's behalf on the proper usage and operating features of the alternate epinephrine auto-injector.
(b) For purposes of this subdivision "epinephrine auto-injector" shall have the same meaning as provided in paragraph (b) of subdivision one of section three thousand-c of the public health law.
§ 2. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD00933-01-1
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the education law, in relation to the substitution of brand name epinephrine auto-injectors with alternate epinephrine auto- injectors for dispensation by pharmacists
Purpose
This legislation will help ensure affordable access to epinephrine.
Summary of provisions
Section 1 of the bill adds a new subdivision 6 to education law § 6816-a to authorize a pharmacist to substitute an alternate generic epinephrine auto-injector containing the same active ingredients, dosage, form and strength as the brand name product prescribed, provided: (1) the pres- criber does not indicate that the prescription must be dispensed as written; (2) the alternate epinephrine auto-injector available would cost less; (3) the pharmacist has advised the purchaser of the avail- ability of an alternate epinephrine auto-injector and obtained consent to dispense the alternate; and (4) the pharmacist has counseled the patient or person authorized to act on the patient's behalf on the prop- er usage and operating features of the alternate epinephrine auto-injec- tor.
Read the full memo (764 words)
Section 2 is the effective date.
Justification
While New York generic substitution law permits pharmacists to dispense a lower cost generic drug for a brand name prescription drug unless the prescriber writes "dispense as written", questions have arisen about whether the current law covers epinephrine auto-injectors which are a combination drug and a device for administering the drug or whether an alternate brand name injector may be substituted where the prescribed injector is not available.
This bill would authorize a pharmacist to substitute an alternate epinephrine auto-injector containing the same active ingredients, where: (1) the prescriber does not indicate that the prescription must be dispensed as written; (2) the alternate epinephrine auto-injector avail- able would cost less; and (3) the patient consents.
The extraordinary price increases of EpiPens by Mylan Pharmaceutical, that made national headlines, have made access to life saving epineph- rine unaffordable for many families. Since acquiring the drug in 2007, Mylan has increased the price of Epipens 600% bringing the cost to over $600. In 2016, Mylan announced they will authorize a generic version of the EpiPen for $300, which is still more than triple the price of EpiPen when they acquired it.
These rate increases hurt all consumers. For those who need this life- saving medication the cost can be prohibitive, even with insurance coverage, depending on the deductible. Some may have to pay the entire cost out-of-pocket, while others will have larger co-pays. Families often need multiple epinephrine auto-injectors available at home, school, or daycare. Insurance may not cover multiple packages. More- over, since they expire annually this becomes a yearly expense. Epinephrine auto-injectors are a necessity forcing families to make difficult decisions to cover these costs. Finally, all consumers are impacted by increased insurance premiums and taxpayer dollars spent on epinephrine auto-injectors by EMTs and the State Medicaid program.
Less expensive epinephrine auto-injector alternatives are available. For example, Impax Laboratories makes an alternate epinephrine auto-in- jector - Adrenaclick - which can be purchased for as little as $140 with a free coupon found on GoodRx. While both products contain epinephrine and are auto-injectors, the injectors differ - Adrenaclick has two caps, while EpiPen has one. Due to this difference in technology, they are considered two different drugs and a pharmacist cannot substitute one for the other. CVS has also recently announced they will offer an alter- nate epinephrine auto-injector for a fraction of the price of EpiPen.
Since there is technically no generic version of the EpiPen, a pharma- cist cannot substitute Adrenaclick if the prescription specifies EpiPen. A pharmacist may only dispense a less expensive generic version of the Epipen if the prescription is written for an epinephrine auto-injector.
Mylan has spent billions of dollars marketing EpiPen. It has almost become synonymous with epinephrine auto-injector. As a result, most prescribers issue prescriptions specifying EpiPens. Many prescribers are not aware that they should or could write epinephrine auto-injector instead. Many families aren't aware to ask for this either.
This legislation will allow a pharmacist to dispense a less costly alternative epinephrine auto-injector under an EpiPen prescription with the consent of the purchaser. In addition, families can request a phar- macist dispense the less expensive alternative without obtaining a new prescription. New York would be joining more than a dozen states that allow for this substitution. We cannot let a technicality come between New Yorkers and affordable access to this life saving medication.
Legislative history
2019-20:S3539 - passed senate 2017-18: S2489A - passed senate 2015-16: S.8189 - Referred to Higher Education
Fiscal implications
None
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.